C07K 14/475
Growth factors
Official title: Growth factors; Growth regulators
C07K14/475 (Growth factors) appears on 4,959 US grants and 6,337 published applications in this corpus.
Search patents in C07K- Granted patents
- 4,959
- Published applications
- 6,337
- Assignees
- 2,285
- Inventors
- 10,427
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 4 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 4 | 0 |
| 1981 | 4 | 0 |
| 1982 | 1 | 0 |
| 1983 | 3 | 0 |
| 1984 | 7 | 0 |
| 1985 | 4 | 0 |
| 1986 | 7 | 0 |
| 1987 | 7 | 0 |
| 1988 | 16 | 0 |
| 1989 | 25 | 0 |
| 1990 | 24 | 0 |
| 1991 | 23 | 0 |
| 1992 | 63 | 0 |
| 1993 | 79 | 0 |
| 1994 | 73 | 0 |
| 1995 | 69 | 0 |
| 1996 | 79 | 0 |
| 1997 | 145 | 0 |
| 1998 | 206 | 0 |
| 1999 | 194 | 0 |
| 2000 | 157 | 0 |
| 2001 | 156 | 34 |
| 2002 | 161 | 255 |
| 2003 | 150 | 453 |
| 2004 | 131 | 302 |
| 2005 | 86 | 274 |
| 2006 | 166 | 241 |
| 2007 | 145 | 218 |
| 2008 | 120 | 230 |
| 2009 | 156 | 281 |
| 2010 | 179 | 263 |
| 2011 | 151 | 247 |
| 2012 | 159 | 189 |
| 2013 | 146 | 227 |
| 2014 | 165 | 244 |
| 2015 | 181 | 243 |
| 2016 | 163 | 278 |
| 2017 | 166 | 232 |
| 2018 | 150 | 231 |
| 2019 | 166 | 260 |
| 2020 | 147 | 260 |
| 2021 | 152 | 267 |
| 2022 | 131 | 246 |
| 2023 | 119 | 245 |
| 2024 | 120 | 251 |
| 2025 | 114 | 221 |
| 2026 | 83 | 145 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C07K 14/50Fibroblast growth factor [fgf]744
- C07K 14/505Erythropoietin [epo]708
- C07K 14/51Bone morphogenetic factor658
- C07K 14/495Transforming growth factor [tgf]592
- C07K 14/485Epidermal growth factor [egf], i.e. urogastrone353
- C07K 14/515Angiogenesic factors287
- C07K 14/48Nerve growth factor [ngf]200
- C07K 14/49Platelet-derived growth factor [pdgf]173
Recent patents
- C-terminal CDNF and MANF fragments, pharmaceutical compositions comprising same and uses thereof15 Sep 2026US 12,735,464 B2MyNeuro Cure Oy
- Method of preparing circular permutation-based functional recombinant human-derived fibroblast growth factor 7 and use thereof15 Sep 2026US 12,735,465 B2Industry Foundation of Chonnam National University
- Oncolytic viruses encoding recombinant transforming growth factor (TGF)-beta monomers and uses thereof15 Sep 2026US 12,735,722 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Transforming growth factor beta-resistant natural killer cells8 Sep 2026US 12,729,228 B2Research Institute At Nationwide Children's Hospital
- Engineered NRG-1 variants with improved selectivity toward ErbB4 but not against ErbB38 Sep 2026US 12,729,229 B2Amgen Inc.
- Fgf21 compound / glp-1r agonist combinations with optimized activity ratio8 Oct 2026US 2026/0306587 A1Sanofi
- Intranasal administration of ngf for the treatment of sensorineural hearing loss8 Oct 2026US 2026/0308216 A1Dompé Farmaceutici S.P.A.
- Metabolic switches for anti-tumor immunity8 Oct 2026US 2026/0308516 A1Cold Spring Harbor Laboratory
- Expression cassette coding for vascular endothelial growth factor8 Oct 2026US 2026/0308618 A1Cornell University
- Aav-epo for treating companion animals1 Oct 2026US 2026/0297149 A1The Trustees of the University of Pennsylvania
Most cited
By later US patents
- Collagen-polymer conjugates778US 5,162,430 ACollagen Corporation · 1992
- Biologically inert, biocompatible-polymer conjugates521US 5,324,775 ACollagen Corporation · 1994
- Method of identifying a stochastically-generated peptide, polypeptide, or protein having ligand binding property and compositions thereof519US 5,723,323 A1998
- Collagen-polymer conjugates471US 5,328,955 ACollagen Corporation · 1994
- Supplemented and unsupplemented tissue sealants, methods of their production and use441US 6,197,325 B1American National Red Cross · 2001